| Literature DB >> 32399171 |
Carina Hellqvist1, Carina Berterö1, Nil Dizdar2, Märta Sund-Levander1, Peter Hagell3.
Abstract
BACKGROUND: Parkinson's disease is a neurodegenerative condition with both physical and mental consequences that affect many aspects of everyday life. Persons with Parkinson's disease and their care partners want guidance from healthcare services in order to develop skills to adjust to life with a long-term condition. The Swedish National Parkinson School is a dyadic self-management programme to support both persons with Parkinson's disease and care partners.Entities:
Year: 2020 PMID: 32399171 PMCID: PMC7210533 DOI: 10.1155/2020/6920943
Source DB: PubMed Journal: Parkinsons Dis ISSN: 2042-0080
Figure 1Flow of participants.
Figure 2Overview of the themes and topics included in Swedish National Parkinson School.
Background characteristics.
| Persons with Parkinson's disease | Care partners | |||||
|---|---|---|---|---|---|---|
| Intervention group ( | Control group ( |
| Intervention group ( | Control group ( |
| |
| Age | 71 (65–75) | 68 (64–75) | 0.506 | 72 (68–77) | 69 (67–74) | 0.112 |
| Male gender, | 24 (41) | 32 (67) | 0.007 | 22 (63) | 7 (24) | 0.002 |
|
| ||||||
| Education, | ||||||
| Primary school (9 years) | 15 (25) | 8 (17) | 0.540 | 12 (34) | 5 (17) | 0.328 |
| High school (11–13 years) | 19 (32) | 18 (38) | 8 (23) | 7 (24) | ||
| University | 25 (42) | 22 (46) | 15 (43) | 16 (55) | ||
|
| ||||||
| Living with someone | 52 (88) | 41 (85) | 0.678 | 34 (97) | 28 (97) | 0.892 |
| Relation to person with PD, | ||||||
| Spouse | — | — | — | 34 (97) | 28 (97) | 1.000 |
| Son/daughter | — | — | 1 (3) | 1 (3) | ||
|
| ||||||
| Housing, | ||||||
| Own house | 33 (56) | 32 (67) | 0.162 | — | — | — |
| Own apartment | 15 (25) | 13 (27) | — | — | ||
| Rental apartment | 11 (19) | 3 (6) | — | — | ||
|
| ||||||
| Comorbidity, | 31 (53) | 27 (60) | 0.506 | 19 (54) | 17 (59) | 0.728 |
| Perceived general health | 1 (1–2) | 2 (1–2) | 0.242 | 2 (2–3) | 2 (2–3) | 0.915 |
| PADLS | 2 (1–2) | 2 (2–2) | 0.918 | — | — | — |
| Hoehn and Yahr stage of PD | 3 (2–3) | — | — | — | — | — |
| Time since diagnosis (years) | 5 (2–7) | 7 (3–8) | 0.147 | — | — | — |
| Perceived PD burden | 2 (2–3) | 2 (2–3) | 0.829 | — | — | — |
| Memory problems in last 30 days | 2 (1–2) | 2 (1–2) | 0.450 | — | — | — |
| Number of medication times/day | 4 (3–5) | 4 (3–6) | 0.984 | — | — | — |
| Motor fluctuations, | 30 (51) | 33 (69) | 0.061 | — | — | — |
| Dyskinesias, | 17 (29) | 21 (45) | 0.091 | — | — | — |
|
| ||||||
| PD medications, | ||||||
| Levodopa | 54 (95) | 45 (94) | 1.000 | — | — | — |
| Dopamine agonists | 31 (54) | 34 (71) | 0.084 | — | — | — |
| COMT inhibitors | 11 (19) | 8 (17) | 0.727 | — | — | — |
| MAO-B inhibitors | 23 (39) | 22 (46) | 0.572 | — | — | — |
| Other | 2 (4) | 2 (4) | 1.000 | — | — | — |
|
| ||||||
| Advanced treatment, | ||||||
| Deep brain stimulation | 1 (2) | 2 (4) | 0.586 | — | — | — |
| S.c. apomorphine infusion | 1 (2) | 1 (2) | 1.000 | — | — | — |
| Levodopa/carbidopa intestinal gel | 4 (7) | 1 (2) | 0.372 | — | — | — |
Data are median (q1-q3) unless otherwise noted. Mann–Whitney U test. Chi-Square test or Fisher's exact test, as appropriate. Possible scores, 0–4 (0 = Poor, 4 = Excellent). Possible scores, 1–5 (1 = No difficulties, 5 = Extreme difficulties). Possible stages, I–V (I = Mild unilateral disease, V = Confined to bed or wheelchair unless aided). Possible scores, 0–4 (0 = None at all, 4 = Extreme). Possible scores, 0–4 (0 = Never, 4 = Always). Other medications included amantadine (n = 2), anticholinergics (n = 1), clozapine (n = 1). PADLS: Parkinson's disease Activities of Daily Living Scale; PD: Parkinson's disease; COMT: Cathechol-O-Methyl Transferase; MAO-B: Mono Amine Oxidase type B; s.c.: subcutaneous.
Differences between and in persons with Parkinson's disease before and after seven weeks of participation in the National Parkinson School (intervention group) and after seven weeks of ordinal care (control group).
| Intervention group ( | Control group ( |
| ||
|---|---|---|---|---|
| Health status (PDQ-8) | Baseline | 28.1 (17.2–39.1) | 25 (12.5–37.5) | 0.301 |
| Follow-up | 23.4 (14.8–37.5) | 23.4 (13.3–37.5) | 0.713 | |
|
|
| 0.644 | ||
|
| ||||
| Health valuation (EQ5D) | Baseline | 0.87 (0.71–0.93) | 0.86 (0.79–0.93) | 0.473 |
| Follow-up | 0.88 (0.78–0.93) | 0.86 (0.79–0.91) | 0.279 | |
|
|
| 0.866 | ||
|
| ||||
| Health education impact (heiQ) | ||||
| Health-directed activities | Baseline | 3.25 (2.75–3.75) | 3.25 (2.75–3.75) | 0.865 |
| Follow-up | 3.25 (2.75–3.75 | 3 (2.75–3.50) | 0.344 | |
|
| 0.323 | 0.437 | ||
|
| ||||
| Positive and active engagement in life | Baseline | 2.8 (2.6–3.2) | 3 (2.6–3.4) | 0.088 |
| Follow-up | 3 (2.8–3.2) | 3 (2.6–3.4) | 0.945 | |
|
| 0.058 | 0.150 | ||
|
| ||||
| Emotional distress | Baseline | 2 (1.5–2.67) | 2.17 (1.83–2.67) | 0.529 |
| Follow-up | 2 (1.5–2.46) | 1.83 (1.33–2.5) | 0.536 | |
|
| 0.436 |
| ||
|
| ||||
| Self-monitoring and insight | Baseline | 2.83 (2.58–3.17) | 3 (2.5–3.17) | 0.445 |
| Follow-up | 3 (2.71–3.17) | 3 (2.67–3.17) | 0.652 | |
|
| 0.572 | 0.285 | ||
|
| ||||
| Constructive attitudes and approaches | Baseline | 3 (2.6–3.2) | 3 (2.8–3.6) | 0.075 |
| Follow-up | 3 (2.8–3.4) | 3.2 (2.8–3.6) | 0.971 | |
|
|
| 0.845 | ||
|
| ||||
| Skills and techniques acquisition | Baseline | 2.5 (2–2.75) | 2.88 (2.5–3.19) |
|
| Follow-up | 3 (2.5–3) | 2.75 (2.44–3) | 0.463 | |
|
|
| 0.464 | ||
|
| ||||
| Social integration and support | Baseline | 3 (2.4–3.6) | 3 (2.8–3.4) | 0.561 |
| Follow-up | 3 (2.8–3.6) | 3 (2.6–3.4) | 0.389 | |
|
| 0.110 | 0.324 | ||
|
| ||||
| Health service navigation | Baseline | 2.9 (2.4–3.2) | 3 (2.8–3.2) | 0.112 |
| Follow-up | 3 (2.6–3.6) | 3 (2.8–3.4) | 0.903 | |
|
| 0.286 | 0.368 | ||
|
| ||||
| Life satisfaction (LiSat-11) | ||||
| Life as a whole | Baseline | 4 (4–5) | 5 (4–5) |
|
| Follow-up | 4.5 (4–5) | 4.5 (4–5) | 0.868 | |
|
| 0.117 |
| ||
|
| ||||
| Vocation | Baseline | 4 (3–5) | 4 (4–5) | 0.078 |
| Follow-up | 4 (4–5) | 4.5 (4–5) | 0.170 | |
|
| 0.159 | 0.157 | ||
|
| ||||
| Economy | Baseline | 5 (4–5) | 5 (5–5) | 0.077 |
| Follow-up | 4 (4–5) | 5 (4–5) |
| |
|
| 0.221 | 0.489 | ||
|
| ||||
| Leisure | Baseline | 4 (4–5) | 5 (4–5) | 0.105 |
| Follow-up | 4 (4–5) | 5 (4–5) | 0.889 | |
|
| 1.000 |
| ||
|
| ||||
| Contacts | Baseline | 5 (4–5) | 5 (4–5) | 0.472 |
| Follow-up | 5 (4–5) | 4 (4–5) | 0.481 | |
|
| 0.815 |
| ||
|
| ||||
| Sexual life | Baseline | 3 (2–4) | 3 (2–4) | 0.314 |
| Follow-up | 3 (2–4) | 3 (2–5) | 0.364 | |
|
| 1.000 | 0.414 | ||
|
| ||||
| ADL | Baseline | 5 (4–5) | 5 (4–6) | 0.289 |
| Follow-up | 5 (4–5) | 5 (4–6) | 0.401 | |
|
| 0.168 | 0.186 | ||
|
| ||||
| Family life | Baseline | 5 (4–6) | 5 (4–6) | 0.203 |
| Follow-up | 5 (4–6) | 5 (5–6) | 0.385 | |
|
| 0.729 | 0.712 | ||
| Partner relationship | Baseline | 5 (4–6) | 6 (4.5–6) | 0.266 |
| Follow-up | 5 (4.5–6) | 5 (5–6) | 0.841 | |
|
| 0.696 | 0.244 | ||
|
| ||||
| Somatic health | Baseline | 4 (3–4) | 4 (4–5) | 0.068 |
| Follow-up | 4 (3–4) | 4 (3–5) | 0.930 | |
|
| 0.263 | 0.054 | ||
|
| ||||
| Psychological health | Baseline | 4 (4–5) | 5 (4–5) | 0.367 |
| Follow-up | 4 (4–5) | 5 (4–5) | 0.088 | |
|
| 0.442 | 0.536 | ||
|
| ||||
| Fatigue (PFS-16) | Baseline | 28 (19–38.8) | 32 (22–38) | 0.814 |
| Follow-up | 32 (20–38) | 27 (16–40) | 0.946 | |
|
| 0.164 | 0.832 | ||
Data are median (q1-q3). Mann–Whitney U test for comparisons between intervention and control groups. Wilcoxon's signed rank test for comparisons between baseline and follow-up within intervention and control groups. Possible scores, 0–100 (100 = worse health status). Possible scores, 0–1 (1 = better valued health state). Possible stages, 1–4 (4 = better; except for emotional well-being, where 1 = better). Possible scores, 1–6 (6 = higher life satisfaction). Possible scores, 0–64 (64 = more fatigue). PDQ-8: the eight-item Parkinson's Disease Questionnaire; EQ5D: the five-dimensional EuroQol Questionnaire; heiQ: Health Education Impact Questionnaire; LiSat-11: the 11-item Life Satisfaction Checklist; PFS-16: the 16-item Parkinson Fatigue Scale.
Differences between care partners and persons with Parkinson's disease before and after seven weeks of participation in the National Parkinson School (intervention group) and after seven weeks of ordinal care (control group).
| Intervention group ( | Control group ( |
| ||
|---|---|---|---|---|
| Health valuation (EQ5D) | Baseline | 0.93 (0.88–0.97) | 0.93 (0.88–0.97) | 0.508 |
| Follow-up | 0.97 (0.88–0.97) | 0.93 (0.88–0.97) | 0.251 | |
|
| 0.837 | 0.944 | ||
|
| ||||
| Life satisfaction (LiSat-11) | ||||
| Life as a whole | Baseline | 5 (4–5) | 5 (4–6) | 0.302 |
| Follow-up | 5 (4–5) | 5 (4–6) | 0.802 | |
|
| 0.414 |
| ||
|
| ||||
| Vocation | Baseline | 5 (4–5) | 5 (4–5.75) | 0.388 |
| Follow-up | 5 (4.25–5) | 5 (4–5) | 0.261 | |
|
| 0.655 | 0.109 | ||
|
| ||||
| Economy | Baseline | 5 (5–5) | 5 (5–5.25) | 0.515 |
| Follow-up | 5 (4–5.25) | 5 (4–5) | 0.945 | |
|
| 0.317 | 0.132 | ||
|
| ||||
| Leisure | Baseline | 5 (4–5) | 5 (4.75–5) | 0.072 |
| Follow-up | 5 (4–5) | 5 (4–5) | 0.964 | |
|
| 0.248 | 0.206 | ||
|
| ||||
| Contacts | Baseline | 5 (5–5) | 5 (4–5.25) | 0.666 |
| Follow-up | 5 (4–5) | 5 (4–6) | 0.671 | |
|
| 0.366 | 0.564 | ||
|
| ||||
| Sexual life | Baseline | 4 (2–5) | 4 (3.5–5) | 0.509 |
| Follow-up | 4 (3–5) | 4 (2.25–5) | 0.776 | |
|
| 0.491 | 0.417 | ||
|
| ||||
| ADL | Baseline | 6 (5–6) | 6 (5–6) | 0.586 |
| Follow-up | 6 (5–6) | 6 (5.25–6) | 0.486 | |
|
| 0.891 | 0.317 | ||
|
| ||||
| Family life | Baseline | 5 (4–6) | 5.5 (5–6) | 0.227 |
| Follow-up | 6 (5–6) | 6 (5–6) | 0.801 | |
|
| 0.290 | 0.655 | ||
|
| ||||
| Partner relationship | Baseline | 6 (5–6) | 6 (5–6) | 0.773 |
| Follow-up | 6 (5–6) | 6 (5–6) | 0.792 | |
|
| 0.763 | 0.705 | ||
|
| ||||
| Somatic health | Baseline | 5 (4–5) | 5 (4–5) | 0.805 |
| Follow-up | 5 (5–5) | 5 (4–5) | 0.659 | |
|
| 0.739 | 0.655 | ||
|
| ||||
| Psychological health | Baseline | 5 (5–6) | 5 (4.75–6) | 0.371 |
| Follow-up | 5 (5–6) | 5 (4.5–6) | 0.851 | |
|
| 0.279 | 0.180 | ||
|
| ||||
| Fatigue (PFS-16) | Baseline | 9 (0–17.75) | 5 (1–19) | 0.661 |
| Follow-up | 6 (0–20) | 11.5 (1.25–25) | 0.296 | |
|
| 0.678 | 0.138 | ||
|
| ||||
| Caregiver burden (ZBI-22) | Baseline | 7 (3–13) | 6 (0.75–12.5) | 0.495 |
| Follow-up | 8 (3.25–12.75) | 5 (2–13.25) | 0.659 | |
|
| 0.090 | 0.548 | ||
Data are median (q1-q3). Mann–Whitney U test for comparisons between intervention and control groups. Wilcoxon's signed rank test for comparisons between baseline and follow-up within intervention and control groups. Possible scores, 0-1 (1 = better valued health state). Possible scores, 1–6 (6 = higher life satisfaction). Possible scores, 0–64 (64 = more fatigue). Possible scores, 0–48 (48 = more burden). EQ5D: the 5-dimensional EuroQol questionnaire; LiSat-11: the 11-item Life Satisfaction Checklist; PFS-16: the 16-item Parkinson Fatigue Scale; zbi-22: the 22-item Zarit Burden Interview.
Results of the heiQ-Program evaluation among persons with Parkinson's disease and care partners after participation in the National Parkinson School.
| Items (abridged) | Persons with Parkinson's disease ( | Care partners ( |
|
|---|---|---|---|
| I will tell people that the NPS is very worthwhile | 5 (4–5) | 5 (4.75–5) | 0.349 |
| The NPS has helped me set reasonable and achievable goals | 4 (4–5) | 5 (4–5) | 0.073 |
| I trust the information and advice given in the NPS | 5 (4–6) | 5 (5–5) | 0.649 |
| NPS leaders were very well-organized | 5 (4–5) | 5 (4–6) | 0.091 |
| It was worth my time and effort to take part in the NPS | 5 (4–6) | 5 (5–6) | 0.405 |
| Difficult topics and discussions were handled well | 5 (4–5) | 5 (5–6) | 0.136 |
| NPS content was very relevant to my situation | 5 (4–5) | 5 (4–5) | 0.309 |
| Everyone had the chance to speak if they wanted to | 5 (5–6) | 5.5 (5–6) | 0.425 |
| The group worked very well together | 5 (4–5) | 5 (4.5–5.5) | 0.158 |
| My understanding of PD has improved | 3 (2–3) | 3 (2–3) | 0.283 |
| My expectations of the NPS were met | 3 (2–3) | 3 (2–3) | 0.177 |
Data are median (q1-q3). Possible scores, 1–6 (1 = Totally disagree, 6 = Totally agree). Study specific items not included in the original heiQ-Program evaluation questionnaire. Possible scores, 1–3 (1 = Disagree, 3 = Agree). Mann–Whitney U test.